MARINUS PHARMACEUTICALS INC's ticker is and the CUSIP is 56854Q200. A total of 90 filers reported holding MARINUS PHARMACEUTICALS INC in Q2 2024. The put-call ratio across all filers is 0.31 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $281,659 | -81.3% | 240,734 | +44.3% | 0.00% | -100.0% |
| Q1 2024 | $1,508,523 | +41.4% | 166,872 | +70.0% | 0.00% | +50.0% |
| Q4 2023 | $1,066,738 | +50.7% | 98,136 | -4.4% | 0.00% | -33.3% |
| Q1 2023 | $707,954 | +300.4% | 102,602 | +131.0% | 0.00% | +200.0% |
| Q4 2022 | $176,800 | +30.0% | 44,422 | +117.9% | 0.00% | 0.0% |
| Q3 2022 | $136,000 | +1.5% | 20,391 | -26.1% | 0.00% | 0.0% |
| Q2 2022 | $134,000 | – | 27,602 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lion Point Capital, LP | 2,145,337 | $17,269,963 | 7.70% |
| Bleichroeder LP | 1,872,463 | $15,073,327 | 3.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 5,204,942 | $41,899,783 | 2.26% |
| Opaleye Management Inc. | 584,000 | $4,701,200 | 1.53% |
| Bain Capital Life Sciences Investors, LLC | 1,431,058 | $11,520,017 | 1.29% |
| Cormorant Asset Management, LP | 2,625,000 | $21,131,250 | 1.23% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 290,000 | $2,337,400 | 0.79% |
| Ikarian Capital, LLC | 746,069 | $6,005,856 | 0.72% |
| Eventide Asset Management | 4,529,997 | $36,466,476 | 0.66% |
| Altium Capital Management LP | 125,033 | $1,006,516 | 0.52% |